Rein Therapeutics, Inc. Operating Expenses
Rein Therapeutics, Inc. (RNTX) reported Operating Expenses of $6.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- Rein Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $6.08M, a 11.57% decline year-over-year.
- Rein Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $5.23M, a 6.76% decline year-over-year.
- Rein Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $32.66M, a 23.69% decline year-over-year.
- Rein Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $5.49M, a 9.54% decline year-over-year.
- Rein Therapeutics, Inc. operating expenses for fiscal 2025 was $50.63M, a 22.24% decline from fiscal 2024.
- Rein Therapeutics, Inc. operating expenses for fiscal 2024 was $65.11M, a 300.05% increase from fiscal 2023.
- Rein Therapeutics, Inc. operating expenses for fiscal 2023 was $16.28M, a 41.13% decline from fiscal 2022.
- Rein Therapeutics, Inc. operating expenses for fiscal 2022 was $27.65M, a 3.92% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $6.08M 10-Q · filed 2026-08-14 | $11.31M 10-Q · filed 2026-08-14 | $43.97M derived: sum of 3 quarters · filed 2026-08-14 | $49.46M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $5.23M 10-Q · filed 2026-05-15 | $37.89M derived: sum of 2 quarters · filed 2026-05-15 | $43.38M derived: sum of 3 quarters · filed 2026-05-15 | $50.25M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $32.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $38.15M derived: sum of 2 quarters · filed 2026-03-26 | $45.02M derived: sum of 3 quarters · filed 2026-08-14 | $50.63M 10-K · filed 2026-03-26 | |
| 2025-09-30 | $5.49M 10-Q · filed 2025-11-14 | $12.36M derived: sum of 2 quarters · filed 2026-08-14 | $17.97M 10-Q · filed 2025-11-14 | $60.77M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $6.87M 10-Q · filed 2026-08-14 | $12.48M 10-Q · filed 2026-08-14 | $55.28M derived: sum of 3 quarters · filed 2026-08-14 | $61.35M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $5.61M 10-Q · filed 2026-05-15 | $48.41M derived: sum of 2 quarters · filed 2026-05-15 | $54.48M derived: sum of 3 quarters · filed 2026-05-15 | $63.52M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $42.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $48.87M derived: sum of 2 quarters · filed 2026-03-26 | $57.91M derived: sum of 3 quarters · filed 2026-03-26 | $65.11M 10-K · filed 2026-03-26 | |
| 2024-09-30 | $6.07M 10-Q · filed 2025-11-14 | $15.11M derived: sum of 2 quarters · filed 2025-11-14 | $22.32M 10-Q · filed 2025-11-14 | $29.61M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $9.04M 10-Q · filed 2025-08-14 | $16.24M 10-Q · filed 2025-08-14 | $23.53M derived: sum of 3 quarters · filed 2025-08-14 | $25.52M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $7.21M 10-Q · filed 2025-05-15 | $14.49M derived: sum of 2 quarters · filed 2025-05-15 | $16.48M derived: sum of 3 quarters · filed 2025-05-15 | $18.47M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $7.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-07 | $9.27M derived: sum of 2 quarters · filed 2025-04-07 | $11.27M derived: sum of 3 quarters · filed 2025-04-07 | $16.28M 10-K · filed 2025-04-07 | |
| 2023-09-30 | $1.98M 10-Q · filed 2024-11-14 | $3.98M derived: sum of 2 quarters · filed 2024-11-14 | $8.99M 10-Q · filed 2024-11-14 | $13.69M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $1.99M 10-Q · filed 2024-08-14 | $7.00M 10-Q · filed 2024-08-14 | $11.71M derived: sum of 3 quarters · filed 2024-08-14 | $18.19M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $5.01M 10-Q · filed 2024-05-15 | $9.71M derived: sum of 2 quarters · filed 2024-05-15 | $16.20M derived: sum of 3 quarters · filed 2024-05-15 | $24.24M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $4.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $11.19M derived: sum of 2 quarters · filed 2024-04-15 | $19.23M derived: sum of 3 quarters · filed 2024-04-15 | $27.65M 10-K · filed 2024-04-15 | |
| 2022-09-30 | $6.48M 10-Q · filed 2023-10-13 | $14.52M derived: sum of 2 quarters · filed 2023-10-13 | $22.94M 10-Q · filed 2023-10-13 | $29.76M derived: sum of 4 quarters · filed 2023-10-13 | |
| 2022-06-30 | $8.04M 10-Q · filed 2023-08-11 | $16.46M 10-Q · filed 2023-08-11 | $23.28M derived: sum of 3 quarters · filed 2023-08-11 | $30.07M derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | $8.42M 10-Q · filed 2023-05-08 | $15.24M derived: sum of 2 quarters · filed 2023-05-08 | $22.03M derived: sum of 3 quarters · filed 2023-05-08 | $28.04M derived: sum of 4 quarters · filed 2023-05-08 | |
| 2021-12-31 | $6.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $13.61M derived: sum of 2 quarters · filed 2023-03-20 | $19.62M derived: sum of 3 quarters · filed 2023-03-20 | $26.61M 10-K · filed 2023-03-20 | |
| 2021-09-30 | $6.79M 10-Q · filed 2022-11-01 | $12.80M derived: sum of 2 quarters · filed 2022-11-01 | $19.79M 10-Q · filed 2022-11-01 | $23.98M derived: sum of 4 quarters · filed 2022-11-01 | |
| 2021-06-30 | $6.01M 10-Q · filed 2022-08-15 | $13.00M 10-Q · filed 2022-08-15 | $17.19M derived: sum of 3 quarters · filed 2022-08-15 | $22.22M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $6.99M 10-Q · filed 2022-05-05 | $11.18M derived: sum of 2 quarters · filed 2022-05-05 | $16.21M derived: sum of 3 quarters · filed 2022-05-05 | $20.61M derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | $4.19M 10-K · filed 2021-03-24 | $9.22M derived: sum of 2 quarters · filed 2021-11-12 | $13.62M derived: sum of 3 quarters · filed 2021-11-12 | $20.50M 10-K · filed 2022-03-28 | |
| 2020-09-30 | $5.03M 10-Q · filed 2021-11-12 | $9.43M derived: sum of 2 quarters · filed 2021-11-12 | $16.30M 10-Q · filed 2021-11-12 | $23.65M derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | $4.40M 10-Q · filed 2021-08-11 | $11.28M 10-Q · filed 2021-08-11 | $18.62M derived: sum of 3 quarters · filed 2021-08-11 | $26.54M derived: sum of 4 quarters · filed 2021-08-11 | |
| 2020-03-31 | $6.88M 10-Q · filed 2021-05-11 | $14.22M derived: sum of 2 quarters · filed 2021-05-11 | $22.14M derived: sum of 3 quarters · filed 2021-05-11 | $29.52M derived: sum of 4 quarters · filed 2021-05-11 | |
| 2019-12-31 | $7.35M 10-K · filed 2021-03-24 | $15.26M derived: sum of 2 quarters · filed 2021-03-24 | $22.64M derived: sum of 3 quarters · filed 2021-03-24 | $29.96M 10-K · filed 2021-03-24 | |
| 2019-09-30 | $7.92M 10-K · filed 2021-03-24 | $15.29M derived: sum of 2 quarters · filed 2021-03-24 | $22.61M 10-Q · filed 2020-11-12 | $29.59M derived: sum of 4 quarters · filed 2021-03-24 | |
| 2019-06-30 | $7.38M 10-K · filed 2021-03-24 | $7.38M 10-Q · filed 2019-08-06 | $14.69M 10-Q · filed 2020-08-05 | $21.68M derived: sum of 3 quarters · filed 2021-03-24 | $29.17M derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-03-31 | $7.31M 10-K · filed 2021-03-24 | $14.29M derived: sum of 2 quarters · filed 2021-03-24 | $21.79M derived: sum of 3 quarters · filed 2021-03-24 | $31.45M derived: sum of 4 quarters · filed 2021-03-24 | |
| 2018-12-31 | $6.98M 10-K · filed 2020-03-30 | $14.48M derived: sum of 2 quarters · filed 2020-03-30 | $24.14M derived: sum of 3 quarters · filed 2020-03-30 | $31.90M 10-K · filed 2020-03-30 | |
| 2018-09-30 | $7.50M 10-K · filed 2020-03-30 | $17.16M derived: sum of 2 quarters · filed 2020-03-30 | $24.92M 10-Q · filed 2019-11-07 | $31.96M derived: sum of 4 quarters · filed 2020-03-30 | |
| 2018-06-30 | $9.66M 10-K · filed 2020-03-30 | $17.42M 10-Q · filed 2019-08-06 | $24.46M derived: sum of 3 quarters · filed 2020-03-30 | $30.89M derived: sum of 4 quarters · filed 2020-03-30 | |
| 2018-03-31 | $7.76M 10-K · filed 2020-03-30 | $14.80M derived: sum of 2 quarters · filed 2020-03-30 | $21.23M derived: sum of 3 quarters · filed 2020-03-30 | $26.18M derived: sum of 4 quarters · filed 2020-03-30 | |
| 2017-12-31 | $7.04M 10-K · filed 2019-03-29 | $13.47M derived: sum of 2 quarters · filed 2019-03-29 | $18.42M derived: sum of 3 quarters · filed 2019-03-29 | $23.01M 10-K · filed 2019-03-29 | |
| 2017-09-30 | $6.43M 10-K · filed 2019-03-29 | $11.38M derived: sum of 2 quarters · filed 2019-03-29 | $15.97M 10-Q · filed 2018-11-07 | $20.41M derived: sum of 4 quarters · filed 2019-03-29 | |
| 2017-06-30 | $4.95M 10-K · filed 2019-03-29 | $9.54M 10-Q · filed 2018-08-07 | $13.99M derived: sum of 3 quarters · filed 2019-03-29 | $18.22M derived: sum of 4 quarters · filed 2019-03-29 | |
| 2017-03-31 | $4.59M 10-K · filed 2019-03-29 | $9.04M derived: sum of 2 quarters · filed 2019-03-29 | $13.27M derived: sum of 3 quarters · filed 2019-03-29 | $18.82M derived: sum of 4 quarters · filed 2019-03-29 | |
| 2016-12-31 | $4.45M 10-K · filed 2018-04-02 | $8.68M derived: sum of 2 quarters · filed 2018-04-02 | $14.23M derived: sum of 3 quarters · filed 2018-04-02 | $18.17M 10-K · filed 2018-04-02 | |
| 2016-09-30 | $4.23M 10-K · filed 2018-04-02 | $9.78M derived: sum of 2 quarters · filed 2018-04-02 | $13.72M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $5.55M 10-K · filed 2018-04-02 | $9.49M 10-Q · filed 2017-08-10 | |||
| 2016-03-31 | $3.94M 10-K · filed 2018-04-02 | ||||
| 2015-12-31 | $12.89M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |